Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
|Videos|November 4, 2022
Dr. John Valvo on who should receive HIFU
Author(s)Urology Times staff
“You can't just have all or none treatments. You've got to have a middle ground for people who are going to look for that,” says John R. Valvo, MD.
Advertisement
In this video, John R. Valvo, MD, discusses an example of a potential candidate for high-intensity focused ultrasound treatment. Valvo is Director of Robotics at Rochester Regional Health in Rochester, New York, a clinical associate professor and Chief of Urology for Via Health in Rochester, and Executive Director of the Polissini Center for Robotic and Minimally Invasive Surgery at Rochester General Hospital.
Advertisement
Related to this article
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Advertisement
Advertisement
Trending on Urology Times
1
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
2
Variation in PSMA PET Adoption for Prostate Cancer Care
3
FDA grants 510(k) clearance to OpenFlo urinary catheter
4
FDA grants fast track designation to VIR-5500 for mCRPC
5